Dr. Todd H. Lanman Presents First-Ever Public Results of the Synergy Disc(R) 1-Level IDE Clinical Trial at DOCS Health's 7th Annual Spine Arthroplasty Summit

November 7, 2025 7:25 PM

Todd H. Lanman, MD, FACS, FAANS, founder of Lanman Spinal Neurosurgery and ADR Spine, presented the first public results today from the Synergy Disc® 1-Level Investigational Device Exemption (IDE) Clinical Trial (NCT 04469231) during the DOCS Health 7th Annual Spine Arthroplasty Summit in Beverly Hills, CA. The pivotal study demonstrated that arthroplasty with Synergy Disc® was statistically superior to anterior cervical discectomy and fusion...

Read more

LipoVive Reviews (URGENT REPORT) Doctor Reveals How This GLP-1 Inspired Formula Targets Belly Fat & Hormonal Imbalance

November 7, 2025 6:00 PM

In 2025, weight-loss conversations no longer revolve around calories, they revolve around hormones. As prescription GLP-1 drugs like Mounjaro and Ozempic capture headlines for rapid fat reduction, millions are now asking whether nature can safely reproduce the same biochemical effect. That question lies at the heart of the LipoVive Reviews 2025 surge across search results. LipoVive positions itself as a plant-based mimic of the GLP-1 and GIP...

Read more

Onco-Innovations' Inka Health Publishes Framework on Transportability of Real-World Evidence and Use in Health Technology Assessment

November 7, 2025 6:00 PM

Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") is pleased to announce that its subsidiary, Inka Health Corp. ("InkaHealth"), has published a technical primer[1] on the transportability of real-world evidence (RWE) titled Transportability of Non-Local Real-World Evidence and Its Relevance to Health Technology Assessment in the Journal of Clinical Evaluative Research (JCER). This primer,...

Read more

Reporting of Transactions Made by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them in Gubra A/S' shares

November 7, 2025 12:15 PM

Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company") hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in the Company and persons closely associated with them in the Company's shares and other financial instruments linked thereto.1.Details of the person discharging managerial responsibilities/person closely associateda)NameMarkus...

Read more

Releaf Dispensary Ltd Announces UK Cannabis Survey: 97% See Quality of Life Gains

November 7, 2025 11:45 AM

It has now been seven years since the legalisation of medical cannabis in the UK, and a new comprehensive study of active patients reveals how it can transform quality of life for many, while illustrating continued social anxieties about its use.The research, conducted by Releaf, the UK's fastest-growing medical cannabis provider, presents a patient demographic that challenges common preconceptions. The majority are middle-aged professionals,...

Read more

Releaf Dispensary Ltd Announces UK Cannabis Survey: 97% See Quality of Life Gains

November 7, 2025 11:45 AM

It has now been seven years since the legalisation of medical cannabis in the UK, and a new comprehensive study of active patients reveals how it can transform quality of life for many, while illustrating continued social anxieties about its use.The research, conducted by Releaf, the UK's fastest-growing medical cannabis provider, presents a patient demographic that challenges common preconceptions. The majority are middle-aged professionals,...

Read more

Releaf Dispensary Ltd Announces UK Cannabis Survey: 97% See Quality of Life Gains

November 7, 2025 11:45 AM

It has now been seven years since the legalisation of medical cannabis in the UK, and a new comprehensive study of active patients reveals how it can transform quality of life for many, while illustrating continued social anxieties about its use.The research, conducted by Releaf, the UK's fastest-growing medical cannabis provider, presents a patient demographic that challenges common preconceptions. The majority are middle-aged professionals,...

Read more

Dr. Patrick Doherty: Advancing Spine Care With Innovation, Compassion and Patient Empowerment

November 7, 2025 9:00 AM

Dr. Patrick Doherty, Associate Professor of Neurosurgery at Yale, is redefining the landscape of spine care by combining the latest medical innovations with a deeply compassionate, patient-centered approach. With over 25 years of experience, Dr. Doherty is recognized not only for his technical expertise but also for his dedication to helping patients take charge of their own health and recovery."My goal is to provide the best possible outcome...

Read more

UniDoc to Exhibit at ANCI 2025 in Bologna, November 12-14

November 7, 2025 8:00 AM

UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or the "Company") will attend and exhibit at the 42nd Annual ANCI Assembly in Bologna, Italy, from November 12-14, 2025.ANCI is the national association of Italian municipalities. The annual assembly convenes mayors and municipal leaders from across Italy. UniDoc will be present at BolognaFiere with an exhibit at Booth #164-166.Key TakeawaysUniDoc exhibiting at ANCI 2025 in Bologna,...

Read more

Veteran Trauma Recovery Takes Center Stage at Cannadelic Global Summit

November 7, 2025 6:00 AM

Florida is home to one of the nation's largest veteran populations - and one of the highest unmet mental health burdens among post-service individuals. This November, the Cannadelic Global Summit will bring forward new pathways of recovery through psychedelic-informed care, trauma integration, peer-based support, somatic healing, and non-pharmaceutical therapeutic models.With the U.S. veteran suicide rate still hovering far above the civilian...

Read more

The Subscription Period in Spago Nanomedical's Rights Issue Begins Today

November 7, 2025 3:10 AM

Today is the first day of the subscription period in Spago Nanomedical AB (publ)'s ("Spago Nanomedical" or the "Company")(STO:SPAGO.ST)(FRA:7UX.F) rights issue of shares of approximately SEK 25 million before transaction costs (the "Rights Issue"), which was resolved by the board on October 29, 2025, based on the authorization received at the Annual General Meeting on May 14, 2025. The subscription period for the Rights Issue runs from November...

Read more

Trading Statement Q3-2025: Expanding Our R&D Activities

November 7, 2025 1:45 AM

Gubra (CPH:GUBRA) - Today, Gubra releases its results for the third quarter of 2025. In September, Gubra welcomed Markus Rohrwild as our new CEO. The third quarter has been characterized by expansion of our R&D activities with key pipeline programs moving forward, not least our internal UCN2 "healthy weight loss" program. For our CRO business, we have seen a small decline in revenue year-over-year, and we expect full-year 2025 revenue for the...

Read more

IRLAB Receives Acceptance for Two Abstracts at AD/PD(TM) 2026: The 20th International Conference on Alzheimer's and Parkinson's Diseases

November 7, 2025 1:20 AM

IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that two abstracts have been accepted for presentation at the international conference AD/PD 2026, to be held in Copenhagen on March 17-21."We are very much looking forward to participating in AD/PD, one of the world's leading scientific meetings in Parkinson's disease research. It provides us the chance...

Read more

President Trump's Decision on Medical Cannabis Will Define His Legacy: Science or Marijuana Policy Stagnation

November 6, 2025 4:50 PM

WASHINGTON, DC / ACCESS Newswire / November 7, 2025 /The future of medical cannabis - and the credibility of America's Marijuana regulatory system - now rests with President Donald J. Trump. After the Department of Justice (DOJ) formally conceded in September that the Drug Enforcement Administration's (DEA) internal court system was unconstitutional, the long-running case of MMJ BioPharma Cultivation has become a defining test of whether the...

Read more

NHI Announces Fourth Quarter 2025 Dividend

November 6, 2025 4:15 PM

National Health Investors, Inc. (NYSE:NHI) announced today that it will pay its fourth quarter dividend of $0.92 per common share on January 30, 2026, to stockholders of record as of December 31, 2025.About NHINational Health Investors, Inc. (NYSE: NHI), established in 1991, is a self-managed real estate investment trust specializing in sale-leaseback, joint venture, mortgage and mezzanine financing of need-driven and discretionary senior...

Read more

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025

November 6, 2025 4:15 PM

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for the three and nine months ended September 30, 2025.Corporate HighlightsAnnounced Groundbreaking Top-line Results from PRIME Clinical StudyReceived gross proceeds of $9.6 million from warrant inducement in September 2025"The...

Read more

NHI Issues Investor Update

November 6, 2025 4:10 PM

National Health Investors, Inc. (NYSE:NHI) has issued the following investor update which can be found at:https://investors.nhireit.com/News/presentations-and-webcasts/default.aspxAbout NHINational Health Investors, Inc. (NYSE: NHI), established in 1991, is a self-managed real estate investment trust specializing in sale-leaseback, joint venture, mortgage and mezzanine financing of need-driven and discretionary senior housing and medical...

Read more

NHI Announces Third Quarter 2025 Results

November 6, 2025 4:05 PM

National Health Investors, Inc. (NYSE:NHI) announced today its results for the three and nine months ended September 30, 2025.CEO Comments"NHI had another strong quarter highlighted by the transition of seven properties to our SHOP portfolio that resulted in consolidated SHOP NOI year-over-year growth of approximately 63%," said Eric Mendelsohn, NHI's President and CEO."We also announced our first SHOP acquisition for $74.3 million which,...

Read more

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025

November 6, 2025 4:05 PM

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended September 30, 2025."Amphastar delivered another strong quarter, led by double-digit growth from BAQSIMI ®, which achieved a 14% increase in revenue compared to...

Read more

Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 6, 2025 4:05 PM

Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update."2025 continues to be a highly productive year with significant accomplishments in both partnered and wholly owned programs," said Dinesh V. Patel, Ph.D., the Company's President and CEO. "In addition to the NDA and EMA submissions for icotrokinra for psoriasis,...

Read more